116 related articles for article (PubMed ID: 31058544)
21. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of prolactin receptor expression in breast cancer subtypes].
Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF
Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231
[TBL] [Abstract][Full Text] [Related]
23. Glycemic index, glycemic load and invasive breast cancer incidence in postmenopausal women: The PREDIMED study.
Castro-Quezada I; Sánchez-Villegas A; Martínez-González MÁ; Salas-Salvadó J; Corella D; Estruch R; Schröder H; Álvarez-Pérez J; Ruiz-López MD; Artacho R; Ros E; Bulló M; Sorli JV; Fitó M; Ruiz-Gutiérrez V; Toledo E; Buil-Cosiales P; García Rodríguez A; Lapetra J; Pintó X; Salaverría I; Tur JA; Romaguera D; Tresserra-Rimbau A; Serra-Majem L;
Eur J Cancer Prev; 2016 Nov; 25(6):524-32. PubMed ID: 26633163
[TBL] [Abstract][Full Text] [Related]
24. Association between mammographic density and tumor marker-defined breast cancer subtypes: a case-control study.
Shin J; Lee JE; Ko HY; Nguyen TL; Nam SJ; Hopper JL; Song YM
Eur J Cancer Prev; 2018 May; 27(3):239-247. PubMed ID: 28957821
[TBL] [Abstract][Full Text] [Related]
25. Carbohydrate Intake, Glycemic Index, and Glycemic Load and the Risk of Breast Cancer among Iranian Women.
Alboghobeish Z; Hekmatdoost A; Jalali S; Ahmadi M; Rashidkhani B
Nutr Cancer; 2021; 73(5):785-793. PubMed ID: 32515614
[TBL] [Abstract][Full Text] [Related]
26. Dietary Carbohydrate, Glycemic Index, Glycemic Load, and Breast Cancer Risk Among Mexican Women.
Amadou A; Degoul J; Hainaut P; Chajes V; Biessy C; Torres Mejia G; Huybrechts I; Moreno Macia H; Ortega C; Angeles-Llerenas A; Romieu I
Epidemiology; 2015 Nov; 26(6):917-24. PubMed ID: 26340313
[TBL] [Abstract][Full Text] [Related]
27. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
31. Night work and breast cancer risk defined by human epidermal growth factor receptor-2 (HER2) and hormone receptor status: A population-based case-control study in France.
Cordina-Duverger E; Koudou Y; Truong T; Arveux P; Kerbrat P; Menegaux F; Guénel P
Chronobiol Int; 2016; 33(6):783-7. PubMed ID: 27078711
[TBL] [Abstract][Full Text] [Related]
32. Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer.
Bandala C; De la Garza-Montano P; Cortes-Algara A; Cruz-Lopez J; Dominguez-Rubio R; Gonzalez-Lopez JN; Cardenas-Rodriguez N; Alfaro-Rodriguez A; Salcedo M; Floriano-Sanchez E; Lara-Padilla E
Asian Pac J Cancer Prev; 2015; 16(18):8397-403. PubMed ID: 26745092
[TBL] [Abstract][Full Text] [Related]
33. ER-/PR+/HER2- breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases.
Arena V; Pennacchia I; Vecchio FM; Carbone A
Breast J; 2019 May; 25(3):381-385. PubMed ID: 30916428
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
35. Molecular Subtypes and Prognosis in Young Mexican Women With Breast Cancer.
Villarreal-Garza C; Mohar A; Bargallo-Rocha JE; Lasa-Gonsebatt F; Reynoso-Noverón N; Matus-Santos J; Cabrera P; Arce-Salinas C; Lara-Medina F; Alvarado-Miranda A; Ramírez-Ugalde MT; Soto-Perez-de-Celis E
Clin Breast Cancer; 2017 Jun; 17(3):e95-e102. PubMed ID: 28065398
[TBL] [Abstract][Full Text] [Related]
36. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer recurrence according to molecular subtype.
Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
[TBL] [Abstract][Full Text] [Related]
38. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.
Parise CA; Caggiano V
Cancer Causes Control; 2019 May; 30(5):417-424. PubMed ID: 30879205
[TBL] [Abstract][Full Text] [Related]
39. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G
Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595
[TBL] [Abstract][Full Text] [Related]
40. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
